Sunday, September 20, 2026

Less Than One Hour Before The Market Open, DocuSign Is Down By 4%

ViaNews Editorial Team

January 2, 2024

Less Than One Hour Before The Market Open, DocuSign Is Down By 4%

(VIANEWS) - The NASDAQ opens in less than one hour and DocuSign's pre-market value is already 4.84% down.

DocuSign's last close was $59.45, 14.4% below its 52-week high of $69.45.

The last session, NASDAQ ended with DocuSign (DOCU) falling 1.25% to $59.45. NASDAQ fell 0.56% to $15,011.35, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session.

About DocuSign

DocuSign, Inc. provides electronic signature solution in the United States and internationally. The company provides DocuSign e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce. It also provides Identify, a signer-identification option for checking government-issued IDs; Standards-Based Signatures, which support signatures that involve digital certificates; and Monitor that uses advanced analytics to track DocuSign eSignature web, mobile, and API account. In addition, the company offers Rooms for Real Estate that provides a way for brokers and agents to manage the entire real estate transaction digitally; DocuSign Federal and DocuSign CLM are FedRAMP, an authorized version of DocuSign eSignature for U.S. federal government agencies; and life sciences modules that support compliance with the electronic signature practices. The company sells its products through direct and partner-assisted sales, and web-based self-service purchasing. The company was incorporated in 2003 and is headquartered in San Francisco, California.

Earnings Per Share

As for profitability, DocuSign has a trailing twelve months EPS of $0.25.

PE Ratio

DocuSign has a trailing twelve months price to earnings ratio of 237.8. Meaning, the purchaser of the share is investing $237.8 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.2%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 1.5% and a negative 6.9%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 2.71B for the twelve trailing months.

Sales Growth

DocuSign's sales growth for the current quarter is 6%.

Yearly Top and Bottom Value

DocuSign's stock is valued at $59.45 at 08:32 EST, way under its 52-week high of $69.45 and way higher than its 52-week low of $38.11.

More news about DocuSign (DOCU).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com